Latest Granulocyte colony-stimulating factor Stories
ResearchMoz.us include new market research report " China Recombinant Protein Drug Industry, 2014-2017: Market Size, Shares, Growth, Analysis, Trends And Forecast" to its huge collection
Surveyed European Oncologists Expect to Use Future Biosimilar G-CSFs in a Greater Proportion of Eligible Patients than Biosimilar MAbs, According to Findings from Decision Resources Group BURLINGTON,
RnRMarketResearch.com adds "Hematopoietic Stem Cell Transplantation – Pipeline Review, H2 2014" to its store.
TOORAK, Australia, March 17, 2014 /PRNewswire/ -- Antisense Therapeutics (ASX:ANP) is pleased to advise that it has commenced dosing in its Phase I Stem Cell Mobilisation (SCM) Human Proof of
Researchers say reduced white blood cell count with chemotherapy could be corrected with appropriate medication. Raleigh, NC (PRWEB) March 03, 2014 Researchers
A European study of compounds designed to stimulate stem cells finds that biologically similar versions work as well as the original. Raleigh, NC (PRWEB) February
Phase 1 Trial of BL-8040 expected to begin in Q2 2014; top-line results expected in H2 2014 JERUSALEM, Jan.
Joseph Poole, M.D., Ph.D., of the Emory University School of Medicine, Atlanta, and colleagues studied whether therapy with granulocyte-macrophage colony stimulating factor (GM-CSF), an agent that functions as a white blood cell growth factor, would improve walking performance in patients with symptomatic peripheral artery disease (a form of vascular disease in which there is partial or total blockage of an artery, usually one leading to a leg or arm).
- A political dynamiter.